Navegando por Palavras-chave "Transplante de célula-tronco hematopoética"

Agora exibindo 1 - 1 de 1
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Transplante de células-tronco hematopoéticas e leucemia mieloide aguda: diretrizes brasileiras
    (Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, 2010-05-01) Silla, Lucia Mariano R.; Dulley, Frederico; Saboya, Rosaura; Paton, Eduardo; Kerbauy, Fábio Rodrigues [UNIFESP]; Arantes, Adriano de Moraes [UNIFESP]; Hamerschlak, Nelson; Hospital de Clínicas de Porto Alegre Serviço de Hematologia e Transplante de Medula Óssea; Universidade de São Paulo (USP); Hospital de Câncer de Barret Hemonúcleo; Universidade Federal de São Paulo (UNIFESP); Associação de Combate ao Câncer em Goiás Hospital Araújo Jorge Serviço de Transplante de Medula Óssea; Hospital Israelita Albert Einstein Programa de Hematologia e Transplante de Medula Óssea
    The objective of this work was to define guidelines for the indication of hematopoietic stem cells transplantation (HSCT) in the treatment of acute myeloid leukemia (AML) in Brazil. The role of HSCT in the treatment of AML was discussed by the authors and presented to the Brazilian Society of Bone Marrow Transplantation in a meeting to formulate and ratify the Brazilian Guidelines on HSCT. This consensus was based on a review of international publications and on the Brazilian experience in HSCT for the treatment of AML. The optimal treatment for AML in first complete remission (1CR) has not been defined yet. There is consensus on the indication of allogeneic HSCT with myeloablative conditioning for patients who present high risk cytogenetic changes. Allogeneic HSCT is not indicated for low cytogenetic risk 1RC patients and, apparently, allogeneic and autologous HSCT and consolidation chemotherapy are similar for intermediate risk patients.